{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:35:28Z","timestamp":1793892928191,"version":"4.8.0"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100020814","name":"MedVal Scientific Information Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020814","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005339","name":"American Academy of Neurology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018439","name":"SK Life Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018439","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.eplepsyres.2023.107185","type":"journal-article","created":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T21:15:36Z","timestamp":1688591736000},"page":"107185","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Pharmacokinetics of cenobamate as monotherapy compared with adjunctive therapy"],"prefix":"10.1016","volume":"195","author":[{"given":"Vijay","family":"Vashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William E.","family":"Rosenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Kamin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.eplepsyres.2023.107185_bib1","first-page":"500","article-title":"Update on antiseizure medications 2022","volume":"28","author":"Abou-Khalil","year":"2022","journal-title":"Contin. (Minne Minn.)"},{"key":"10.1016\/j.eplepsyres.2023.107185_bib2","article-title":"Cenobamate: a new adjunctive agent for drug-resistant focal onset epilepsy","author":"Buckley","year":"2020","journal-title":"Ann. Pharm."},{"issue":"22","key":"10.1016\/j.eplepsyres.2023.107185_bib3","doi-asserted-by":"crossref","first-page":"e2311","DOI":"10.1212\/WNL.0000000000009530","article-title":"Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures","volume":"94","author":"Chung","year":"2020","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.eplepsyres.2023.107185_bib4","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1111\/epi.17007","article-title":"Long-term safety of adjunctive cenobamate in patients with uncontrolled focal seizures: open-label extension of a randomized clinical study","volume":"62","author":"French","year":"2021","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2023.107185_bib5","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.seizure.2016.11.022","article-title":"Drug development for refractory epilepsy: the past 25 years and beyond","volume":"44","author":"Golyala","year":"2017","journal-title":"Seizure"},{"issue":"suppl 15","key":"10.1016\/j.eplepsyres.2023.107185_bib6","first-page":"P1.5","article-title":"The pharmacokinetics of cenobamate in special populations [abstract]","volume":"92","author":"Greene","year":"2019","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.eplepsyres.2023.107185_bib7","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/cts.13204","article-title":"Effect of cenobamate on the single-dose pharmacokinetics of multiple cytochrome P450 probes using a cocktail approach in healthy subjects","volume":"15","author":"Greene","year":"2022","journal-title":"Clin. Transl. Sci."},{"issue":"10","key":"10.1016\/j.eplepsyres.2023.107185_bib8","doi-asserted-by":"crossref","first-page":"e989","DOI":"10.1212\/WNL.0000000000200792","article-title":"Long-term efficacy and safety from an open-label extension of adjunctive cenobamate in patients with uncontrolled focal seizures","volume":"99","author":"Klein","year":"2022","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.eplepsyres.2023.107185_bib9","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1474-4422(19)30399-0","article-title":"Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial","volume":"19","author":"Krauss","year":"2020","journal-title":"Lancet Neurol."},{"issue":"12","key":"10.1016\/j.eplepsyres.2023.107185_bib10","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S1474-4422(15)00229-X","article-title":"Is a separate monotherapy indication warranted for antiepileptic drugs?","volume":"14","author":"Mintzer","year":"2015","journal-title":"Lancet Neurol."},{"issue":"6","key":"10.1016\/j.eplepsyres.2023.107185_bib11","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s40263-021-00819-8","article-title":"Pharmacology of cenobamate: mechanism of action, pharmacokinetics, drug-drug interactions and tolerability","volume":"35","author":"Roberti","year":"2021","journal-title":"CNS Drugs"},{"issue":"12","key":"10.1016\/j.eplepsyres.2023.107185_bib12","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1111\/epi.17092","article-title":"Post-hoc analysis of a phase 3, multicenter, open-label study of cenobamate for treatment of uncontrolled focal seizures: effects of dose adjustments of concomitant antiseizure medications","volume":"62","author":"Rosenfeld","year":"2021","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2023.107185_bib13","series-title":"XCOPRI\u00ae (Cenobamate Tablets), for Oral Use, CV [Prescribing Information]","author":"SK Life Science, Inc","year":"2022"},{"key":"10.1016\/j.eplepsyres.2023.107185_bib14","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1007\/s40120-022-00400-5","article-title":"Dose adjustment of concomitant antiseizure medications during cenobamate treatment: expert opinion consensus recommendations","volume":"11","author":"Smith","year":"2022","journal-title":"Neurol. Ther."},{"issue":"6","key":"10.1016\/j.eplepsyres.2023.107185_bib15","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/epi.16525","article-title":"Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open-label safety study","volume":"61","author":"Sperling","year":"2020","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.eplepsyres.2023.107185_bib16","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2174\/157015909788848866","article-title":"Antiepileptic drug monotherapy: the initial approach in epilepsy management","volume":"7","author":"St. Louis","year":"2009","journal-title":"Curr. Neuropharmacol."},{"issue":"4","key":"10.1016\/j.eplepsyres.2023.107185_bib17","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/cpdd.769","article-title":"Pharmacokinetics of cenobamate: results from single and multiple oral ascending-dose studies in healthy subjects","volume":"9","author":"Vernillet","year":"2020","journal-title":"Clin. Pharm. Drug Dev."},{"issue":"2","key":"10.1016\/j.eplepsyres.2023.107185_bib18","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/cts.13167","article-title":"Pharmacokinetics and safety of cenobamate, a novel antiseizure medication, in healthy Japanese, and an ethnic comparison with healthy non-Japanese","volume":"15","author":"Yang","year":"2022","journal-title":"Clin. Transl. Sci."}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121123001109?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121123001109?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:49:36Z","timestamp":1760276976000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121123001109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":18,"alternative-id":["S0920121123001109"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2023.107185","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics of cenobamate as monotherapy compared with adjunctive therapy","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2023.107185","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107185"}}